Company Overview - Gyre Therapeutics is a self-sustainable, commercial-stage biotechnology company focused on chronic organ diseases, headquartered in San Diego, CA [1][3] - The company is developing F351 (Hydronidone) for MASH-associated fibrosis in the U.S. and has a diverse pipeline in the PRC through its subsidiary Gyre Pharmaceuticals [3][4] Leadership Changes - Ping Zhang has been appointed as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee [1] - Ying Luo, Ph.D., resigned as Chairman of the Board to focus on other responsibilities at GNI Group Ltd, with Songjiang Ma appointed as the new Chairman of Gyre Pharmaceuticals [1][3] Financial Performance - Gyre Pharmaceuticals, a subsidiary of Gyre Therapeutics, reported net sales of $112.1 million in 2023 for its flagship product ETUARY® [4] - F351 is currently in a Phase 3 clinical trial for CHB-associated liver fibrosis in the PRC, with topline data expected by early 2025 [4] Product Development - Gyre Therapeutics is advancing F351 based on mechanistic studies and clinical studies related to MASH and CHB-induced liver fibrosis [3] - The company is also developing treatments for other conditions such as COPD, PAH, and ALF/ACLF [4]
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors